M. de Boer
-
Geurts, S. M. E., Ibragimova, K. I. E., Ding, N., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., van de Wouw, A. J., Maaskant, S. A. J. G., Teeuwen-Dedroog, N. J. A., van Nijnatten, T. J. A., de Boer, M., & Tjan-Heijnen, V. C. G. (2024). Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+?metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Research and Treatment, 205(2), 287-302. https://doi.org/10.1007/s10549-023-07235-0More information about this publication
-
van Roozendaal, L. M., Vane, M. L. G., Colier, E., Strobbe, L. J. A., de Boer, M., Sonke, G., Van Maaren, M. C., & Smidt, M. L. (2024). Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed. Breast Cancer Research and Treatment, 203(1), 103-110. https://doi.org/10.1007/s10549-023-07128-2More information about this publication
-
Voorwerk, L., Isaeva, O. I. I., Horlings, H. M. M., Balduzzi, S., Chelushkin, M., Bakker, N. A. M., Champanhet, E., Garner, H., Sikorska, K., Loo, C. E. E., Kemper, I., Mandjes, I. A. M., de Maaker, M., van Geel, J. J. L., Boers, J., de Boer, M., Salgado, R., van Dongen, M. G. J., Sonke, G. S. S., ... Kok, M. (2023). PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nature Cancer, 4(4), 535–549. https://doi.org/10.1038/s43018-023-00542-xMore information about this publication
-
Rugo, H. S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Bachelot, T., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., De Laurentiis, M., Schwartz, G. N., Pluard, T. J., Ricci, F., Gwin, W. R., Levy, C., Brown-Glaberman, U., Ferrero, J.-M., ... SOPHIA Study Group (2023). Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of Clinical Oncology, 41(2), 198-205. https://doi.org/10.1200/JCO.21.02937More information about this publication
-
de Mooij, C. M., van Nijnatten, T. J. A., Goorts, B., Kooreman, L. F. S., Raymakers, I. W. M., van Meijl, S. P. L., de Boer, M., Keymeulen, K. B. M. I., Wildberger, J. E., Mottaghy, F. M., Lobbes, M. B. I., & Smidt, M. L. (2023). Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer. Cancers, 15(2), Article 401. https://doi.org/10.3390/cancers15020401More information about this publication
-
Hillege, L., Waelen, J., Ziemons, J., Aarnoutse, R., De Vos-Geelen, J., De Boer, M., Van Riet, Y., Vincent, J., Venema, K., Rensen, S., Simpson, J., Redinbo, M., Penders, J., & Smidt, M. (2022). Bacterial beta-glucuronidase activity in postmenopausal breast cancer patients: a pilot study. European Journal of Cancer, 175, S84-S84. https://doi.org/10.1016/S0959-8049(22)01578-7More information about this publication
-
Simons, J. M., van Nijnatten, T. J. A., van der Pol, C. C., van Diest, P. J., Jager, A., van Klaveren, D., Kam, B. L. R., Lobbes, M. B. I., de Boer, M., Verhoef, C., Sars, P. R. A., Heijmans, H. J., van Haaren, E. R. M., Vles, W. J., Contant, C. M. E., Menke-Pluijmers, M. B. E., Smit, L. H. M., Kelder, W., Boskamp, M., ... Smidt, M. L. (2022). Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surgery, 157(11), 991-999. https://doi.org/10.1001/jamasurg.2022.3907More information about this publication
-
Aarnoutse, R., Ziemons, J., Hillege, L. E., de Vos-Geelen, J., de Boer, M., Bisschop, S. M. P., Vriens, B. E. P. J., Vincent, J., van de Wouw, A. J., Le, G. N., Venema, K., Rensen, S. S., Penders, J., & Smidt, M. L. (2022). Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy. npj Breast Cancer, 8(1), Article 89. https://doi.org/10.1038/s41523-022-00455-5More information about this publication
-
van Barele, M., Rieborn, A., Heemskerk-Gerritsen, B. A. M., Obdeijn, I.-M., Koppert, L. B., Loo, C. E., Tollenaar, R. A. E. M., Ausems, M. G. E. M., van de Beek, I., Berger, L. P. V., de Boer, M., van Hest, L. P., Kets, C. M., Rookus, M., Schmidt, M. K., Jager, A., Hooning, M. J., & HEBON (2022). Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. Breast Cancer Research and Treatment, 194(1), 159-170. https://doi.org/10.1007/s10549-022-06608-1More information about this publication
-
Meegdes, M., Geurts, S. M. E., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., Winkel, L. M. H., Teeuwen, N. J. A., Boer, M., & Tjan-Heijnen, V. C. G. (2022). The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry. International Journal of Cancer, 150(1), 124-131. https://doi.org/10.1002/ijc.33785More information about this publication
M. de Boer
Assistant Professor
Interne Geneeskunde
School for Cardiovascular Diseases
Fac. Health, Medicine and Life Sciences